OC
SPRY icon

Oppenheimer & Co’s ARS Pharmaceuticals SPRY Stock Holding History

Oppenheimer & Co’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,439
Closed -$99.9K – 1831
2026
Q1 		$99.9K Sell
12,439
-5,419
-30% -$51.9K ﹤0.01% 1643
2025
Q4 		$208K Buy
17,858
+5,344
+43% +$52K ﹤0.01% 1421
2025
Q3 		$126K Hold
12,514
– – ﹤0.01% 1595
2025
Q2 		$218K Sell
12,514
-2,500
-17% -$36.1K ﹤0.01% 1471
2025
Q1 		$189K Buy
+15,014
New +$181K ﹤0.01% 1467

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Oppenheimer & Co's SPRY Position: Q2 2026 in Review

Oppenheimer & Co sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 12,439 shares — an estimated $99.9K sold.

Oppenheimer & Co first reported a position in SPRY in Q1 2025 and held it in 5 quarters. The position peaked at $218K in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Oppenheimer & Co reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 12,439 ARS Pharmaceuticals shares in Q2 2026, an estimated $99.9K.
  • Oppenheimer & Co first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Oppenheimer & Co's ARS Pharmaceuticals position peaked at $218K in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.